A Study to Compare the Effectiveness and Safety of IBI310 Combined With Sintilimab Versus Sorafenib in the First-line Treatment of Advanced HCC
Innovent Biologics (Suzhou) Co. Ltd.
Innovent Biologics (Suzhou) Co. Ltd.
St. Jude Children's Research Hospital
Bristol-Myers Squibb
University of Florida
Institut du Cancer de Montpellier - Val d'Aurelle
Institut du Cancer de Montpellier - Val d'Aurelle
Roswell Park Cancer Institute
Radiation Therapy Oncology Group
AstraZeneca
Bristol-Myers Squibb
Children's Oncology Group
Exelixis
Mirror Biologics, Inc.
BeiGene
The University of Texas Health Science Center at San Antonio
National Cancer Institute (NCI)
AbbVie
Thomas Jefferson University
Memorial Sloan Kettering Cancer Center
Tongji Hospital
Humanity & Health Medical Group Limited